
Lee Mozessohn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8825891/publications.pdf Version: 2024-02-01



LEE MOZESSOHN

#	Article	IF	CITATIONS
1	Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. Haematologica, 2022, 107, 1172-1180.	1.7	21
2	Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States. Blood Advances, 2022, 6, 1126-1136.	2.5	8
3	The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. Annals of Hematology, 2022, 101, 1023-1030.	0.8	3
4	Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 635-642.e9.	2.3	6
5	Patientâ€reported fatigue refines prognosis in higherâ€risk myelodysplastic syndromes (MDS): a MDSâ€CAN study. British Journal of Haematology, 2021, 194, 319-324.	1.2	6
6	Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leukemia and Lymphoma, 2021, 62, 1-8.	0.6	0
7	Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast–Count Acute Myeloid Leukemia. JCO Oncology Practice, 2021, 17, e517-e525.	1.4	4
8	Shorter Diagnosis-to-Treatment Interval in Diffuse Large B-Cell Lymphoma is Associated With Inferior Overall Survival in a Large, Population-Based Registry. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 719-725.	2.3	5
9	The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes. Blood, 2021, 138, 3064-3064.	0.6	1
10	Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the â€~real-world'. Leukemia and Lymphoma, 2020, 61, 1445-1454.	0.6	5
11	Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada. Leukemia and Lymphoma, 2020, 61, 1908-1919.	0.6	9
12	Statin and cyclooxygenaseâ€2 inhibitors improve survival in newly diagnosed diffuse large Bâ€cell lymphoma: a large populationâ€based study of 4913 subjects. British Journal of Haematology, 2020, 191, 396-404.	1.2	19
13	Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study. Blood, 2020, 136, 41-43.	0.6	1
14	High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS. Blood, 2020, 136, 47-48.	0.6	0
15	Statin and COX-2 Inhibitor Exposure Is Associated with Improved Survival in 4913 Newly Diagnosed DLBCL Patients: A Large Population Based Study. Blood, 2019, 134, 3476-3476.	0.6	0
16	Azacitidine in the â€~realâ€world': an evaluation of 1101 higherâ€risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. British Journal of Haematology, 2018, 181, 803-815.	1.2	45
17	Response. Journal of the National Cancer Institute, 2017, 109, .	3.0	0
18	The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study. Journal of the National Cancer Institute, 2017, 109, djw226.	3.0	22

Lee Mozessohn

#	Article	IF	CITATIONS
19	Azacitidine Use in the Real World Does Not Replicate AZA-001 Results in Higher Risk MDS/Low Blast Count AML: An Audit of 1101 Patients in the Cancer Care Ontario Registry. Blood, 2016, 128, 4338-4338.	0.6	0
20	Hepatitis B reactivation in HBsAgâ€negative/HBcAbâ€positive patients receiving rituximab for lymphoma: a metaâ€analysis. Journal of Viral Hepatitis, 2015, 22, 842-849.	1.0	107
21	Combined Modality Therapy in the Upfront Treatment of Patients with Primary Central Nervous System Lymphoma: A Systematic Review. Blood, 2015, 126, 5606-5606.	0.6	0
22	The Association of Dyslipidemia with the Development of Chronic Lymphocytic Leukemia: A Population-Based Study. Blood, 2015, 126, 5268-5268.	0.6	0
23	Management of Severe Dabigatran-Related Hemorrhage: Case Report, Considerations for Management, and Recommendations. Canadian Journal of Hospital Pharmacy, 2014, 67, 43-7.	0.1	5
24	Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis. Leukemia and Lymphoma, 2014, 55, 2502-2507.	0.6	31
25	Polyneuropathy: a poetic diagnosis. BMJ Case Reports, 2012, 2012, bcr1220115421-bcr1220115421.	0.2	0
26	Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis. Blood, 2011, 118, 4981-4981.	0.6	4
27	Publication Patterns of Cancer Cost-Effectiveness Studies Presented at the American Society of Hematology: Timeliness of Publication, Quality and Possible Bias Blood, 2010, 116, 3816-3816.	0.6	1
28	Factors Affecting Knowledge of Sexually Transmitted Infection Transmissibility in Healthcare Providers: Results From a National Survey. Sexually Transmitted Diseases, 2005, 32, 619-624.	0.8	8